Mizuho initiated coverage of Dentsply Sirona (XRAY) with a Neutral rating and $21 price target Dentsply Sirona has historically benefitted from its research and development innovation, which may continue with the recent launch of Primescan 2, the analyst tells investors in a research note. However, the firm believes Dentsply is witnessing economic-related softness in both its dental consumables and equipment franchises, and points out the company also has recently voluntarily temporarily suspended its Byte clear aligner franchise.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on XRAY:
- Patterson Companies initiated with a Neutral at Mizuho
- Dentsply Sirona Inc. Class Action: Levi & Korsinsky LLP Reminds Dentsply Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 27, 2025 – XRAY
- Dentsply Sirona Appoints Interim CFO Amid Investigation
- Dentsply Sirona appoints Cueto as interim Chief Financial Officer
- Dentsply Sirona price target lowered to $24 from $36 at Barrington
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
